https://edgen.beta.edgen.tech/news/post/veracyte-to-present-data-from-2-phase-iii-cancer-trials-at-asco-20262026-05-21T22:25:19.439Zdaily1Edgen Stocken2026-05-21T22:25:19.439+00:00Veracyte to Present Data From 2 Phase III Cancer Trials at ASCO 2026https://static.edgen.tech/news/images/veracyte-to-present-data-from-2-phase-iii-cancer-trials-at-asco-2026-20260521.pngVeracyte to Present Data From 2 Phase III Cancer Trials at ASCO 2026 https://edgen.beta.edgen.tech/news/post/aktis-aky-2519-shows-404-suvmax-uptake-in-first-human-cancer-trial2026-05-21T22:00:37.246Zdaily1Edgen Stocken2026-05-21T22:00:37.246+00:00Aktis' AKY-2519 Shows 40.4 SUVmax Uptake in First Human Cancer Trialhttps://static.edgen.tech/news/images/aktis-aky-2519-shows-404-suvmax-uptake-in-first-human-cancer-trial-20260521.pngAktis' AKY-2519 Shows 40.4 SUVmax Uptake in First Human Cancer Trial https://edgen.beta.edgen.tech/news/post/zoom-raises-fy2027-forecast-to-over-5-billion-on-ai-demand2026-05-21T21:59:44.247Zdaily1Edgen Stocken2026-05-21T21:59:44.247+00:00Zoom raises FY2027 forecast to over $5 billion on AI demandhttps://static.edgen.tech/news/images/zoom-raises-fy2027-forecast-to-over-5-billion-on-ai-demand-20260521.pngZoom raises FY2027 forecast to over $5 billion on AI demand https://edgen.beta.edgen.tech/news/post/nuvalent-to-show-40-response-rate-for-zidesamtinib-pivotal-lung-cancer-data-at-asco2026-05-21T21:59:20.743Zdaily1Edgen Stocken2026-05-21T21:59:20.743+00:00Nuvalent to show 40% response rate for zidesamtinib, pivotal lung cancer data at ASCOhttps://static.edgen.tech/news/images/nuvalent-to-show-40-response-rate-for-zidesamtinib-pivotal-lung-cancer-data-at-asco-20260521.pngNuvalent to show 40% response rate for zidesamtinib, pivotal lung cancer data at ASCO https://edgen.beta.edgen.tech/news/post/amex-exploration-secures-c59-million-to-fund-perron-gold-project2026-05-21T21:56:33.236Zdaily1Edgen Stocken2026-05-21T21:56:33.236+00:00Amex Exploration secures C$59 million to fund Perron gold projecthttps://static.edgen.tech/news/images/amex-exploration-secures-c59-million-to-fund-perron-gold-project-20260521.pngAmex Exploration secures C$59 million to fund Perron gold project https://edgen.beta.edgen.tech/news/post/turkish-stocks-plunge-6-after-court-ousts-opposition-leader2026-05-21T21:38:28.044Zdaily1Edgen Stocken2026-05-21T21:38:28.044+00:00Turkish Stocks Plunge 6% After Court Ousts Opposition Leaderhttps://static.edgen.tech/news/images/turkish-stocks-plunge-6-after-court-ousts-opposition-leader-20260521.pngTurkish Stocks Plunge 6% After Court Ousts Opposition Leader https://edgen.beta.edgen.tech/news/post/black-diamond-rises-on-152-month-cancer-trial-result2026-05-21T21:33:26.247Zdaily1Edgen Stocken2026-05-21T21:33:26.247+00:00Black Diamond Rises on 15.2-Month Cancer Trial Resulthttps://static.edgen.tech/news/images/black-diamond-rises-on-152-month-cancer-trial-result-20260521.pngBlack Diamond Rises on 15.2-Month Cancer Trial Result https://edgen.beta.edgen.tech/news/post/why-a-9010-portfolio-may-be-better-than-6040-for-some-investors2026-05-21T21:32:58.040Zdaily1Edgen Stocken2026-05-21T21:32:58.040+00:00Why a 90/10 portfolio may be better than 60/40 for some investorshttps://static.edgen.tech/news/images/why-a-9010-portfolio-may-be-better-than-6040-for-some-investors-20260521.pngWhy a 90/10 portfolio may be better than 60/40 for some investors https://edgen.beta.edgen.tech/news/post/merck-lung-cancer-combo-with-kelun-hits-70-response-rate2026-05-21T21:32:56.040Zdaily1Edgen Stocken2026-05-21T21:32:56.040+00:00Merck Lung Cancer Combo With Kelun Hits 70% Response Ratehttps://static.edgen.tech/news/images/merck-lung-cancer-combo-with-kelun-hits-70-response-rate-20260521.pngMerck Lung Cancer Combo With Kelun Hits 70% Response Rate https://edgen.beta.edgen.tech/news/post/imax-surges-15-on-reports-of-a-potential-sale2026-05-21T21:30:24.644Zdaily1Edgen Stocken2026-05-21T21:30:24.644+00:00IMAX Surges 15% on Reports of a Potential Salehttps://static.edgen.tech/news/images/imax-surges-15-on-reports-of-a-potential-sale-20260521.pngIMAX Surges 15% on Reports of a Potential Sale https://edgen.beta.edgen.tech/news/post/bicara-cancer-drug-doubles-survival-rate-to-31-in-head-and-neck-trial2026-05-21T21:29:39.032Zdaily1Edgen Stocken2026-05-21T21:29:39.032+00:00Bicara Cancer Drug Doubles Survival Rate to 31% in Head and Neck Trialhttps://static.edgen.tech/news/images/bicara-cancer-drug-doubles-survival-rate-to-31-in-head-and-neck-trial-20260521.pngBicara Cancer Drug Doubles Survival Rate to 31% in Head and Neck Trial https://edgen.beta.edgen.tech/news/post/syndax-to-present-new-revuforj-data-from-4-leukemia-trials-at-asco2026-05-21T21:28:58.631Zdaily1Edgen Stocken2026-05-21T21:28:58.631+00:00Syndax to Present New Revuforj Data From 4 Leukemia Trials at ASCOhttps://static.edgen.tech/news/images/syndax-to-present-new-revuforj-data-from-4-leukemia-trials-at-asco-20260521.pngSyndax to Present New Revuforj Data From 4 Leukemia Trials at ASCO https://edgen.beta.edgen.tech/news/post/remix-drug-shows-43-response-rate-in-rare-cancer-trial2026-05-21T21:26:22.429Zdaily1Edgen Stocken2026-05-21T21:26:22.429+00:00Remix drug shows 43% response rate in rare cancer trialhttps://static.edgen.tech/news/images/remix-drug-shows-43-response-rate-in-rare-cancer-trial-20260521.pngRemix drug shows 43% response rate in rare cancer trial https://edgen.beta.edgen.tech/news/post/akaris-cancer-drug-shows-high-synergy-with-kras-inhibitors2026-05-21T21:26:17.030Zdaily1Edgen Stocken2026-05-21T21:26:17.030+00:00Akari's Cancer Drug Shows High Synergy With KRAS Inhibitorshttps://static.edgen.tech/news/images/akaris-cancer-drug-shows-high-synergy-with-kras-inhibitors-20260521.pngAkari's Cancer Drug Shows High Synergy With KRAS Inhibitors https://edgen.beta.edgen.tech/news/post/dow-surges-351-points-to-new-record-as-investors-rotate-to-tech2026-05-21T21:25:29.242Zdaily1Edgen Stocken2026-05-21T21:25:29.242+00:00Dow Surges 351 Points to New Record as Investors Rotate to Techhttps://static.edgen.tech/news/images/dow-surges-351-points-to-new-record-as-investors-rotate-to-tech-20260521.pngDow Surges 351 Points to New Record as Investors Rotate to Tech https://edgen.beta.edgen.tech/news/post/seer-rejects-radoff-jecs-240-per-share-takeover-bid2026-05-21T20:56:36.236Zdaily1Edgen Stocken2026-05-21T20:56:36.236+00:00Seer Rejects Radoff-JEC’s $2.40 Per Share Takeover Bidhttps://static.edgen.tech/news/images/seer-rejects-radoff-jecs-240-per-share-takeover-bid-20260521.pngSeer Rejects Radoff-JEC’s $2.40 Per Share Takeover Bid https://edgen.beta.edgen.tech/news/post/lucid-group-faces-fraud-inquiry-after-revenue-miss-sinks-stock-72026-05-21T20:55:35.432Zdaily1Edgen Stocken2026-05-21T20:55:35.432+00:00Lucid Group faces fraud inquiry after revenue miss sinks stock 7%https://static.edgen.tech/news/images/lucid-group-faces-fraud-inquiry-after-revenue-miss-sinks-stock-7-20260521.pngLucid Group faces fraud inquiry after revenue miss sinks stock 7% https://edgen.beta.edgen.tech/news/post/baycom-stock-drops-11-as-law-firm-probes-executive-exodus2026-05-21T20:55:25.840Zdaily1Edgen Stocken2026-05-21T20:55:25.840+00:00BayCom stock drops 11% as law firm probes executive exodushttps://static.edgen.tech/news/images/baycom-stock-drops-11-as-law-firm-probes-executive-exodus-20260521.pngBayCom stock drops 11% as law firm probes executive exodus https://edgen.beta.edgen.tech/news/post/carmax-faces-investor-investigation-after-stock-plunges-152026-05-21T20:55:23.045Zdaily1Edgen Stocken2026-05-21T20:55:23.045+00:00CarMax Faces Investor Investigation After Stock Plunges 15%https://static.edgen.tech/news/images/carmax-faces-investor-investigation-after-stock-plunges-15-20260521.pngCarMax Faces Investor Investigation After Stock Plunges 15% https://edgen.beta.edgen.tech/news/post/abbvies-boey-gets-positive-eu-opinion-for-30-markets2026-05-21T20:31:25.639Zdaily1Edgen Stocken2026-05-21T20:31:25.639+00:00AbbVie's Boey Gets Positive EU Opinion for 30 Marketshttps://static.edgen.tech/news/images/abbvies-boey-gets-positive-eu-opinion-for-30-markets-20260521.pngAbbVie's Boey Gets Positive EU Opinion for 30 Markets